Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 7/20 | 0.55 |
| ▸ | PGR | P06401 | 3/20 | 0.49 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.42 |
| ▸ | AXL | P30530 | 1/20 | 0.41 |
| ▸ | DHPS | P49366 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6403528 | 0.89 | NR3C1 (0.63) | NR3C1PGRAXLDHPSTRPV1 | |
| SCHEMBL5802391 | 0.88 | NR3C1 (0.69) | NR3C1PGRNR3C2TRPV1 | |
| SCHEMBL6410296 | 0.88 | NR3C1 (0.59) | NR3C1PGRNR3C2TRPV1 | |
| SCHEMBL5800297 | 0.88 | NR3C1 (0.48) | NR3C1PGRNR3C2DHPSTRPV1 | |
| SCHEMBL6409205 | 0.88 | NR3C1 (0.48) | NR3C1PGRNR3C2AXLDHPS | |
| SCHEMBL6404771 | 0.87 | NR3C1 (0.49) | NR3C1PGRDHPSTRPV1HDAC1 | |
| SCHEMBL6405434 | 0.87 | NR3C1 (0.52) | NR3C1PGRAXLDHPSTRPV1 | |
| SCHEMBL5777416 | 0.87 | NR3C1 (0.55) | NR3C1PGRNR3C2 | |
| SCHEMBL5801258 | 0.84 | NR3C1 (0.49) | NR3C1PGRAXLDHPSTRPV1 | |
| SCHEMBL5801078 | 0.84 | NR3C1 (0.52) | NR3C1PGRDHPSTRPV1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1638945-A1 | HETEROCYCLICALLY SUBSTITUTED PENTANOL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS ANTI-INFLAMMATORY AGENTS | Schering Aktiengesellschaft (DE) | 2006-03-29 | — | — | EP | disclosed |
| US-20050090559-A1 | Heterocyclically-substituted pentanol derivatives, process for their production and their use as anti-inflammatory agents | SCHERING AG (DE) | 2005-04-28 | — | — | US | disclosed |
| WO-2005003098-A1 | HETEROCYCLICALLY SUBSTITUTED PENTANOL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090559-A1 | Heterocyclically-substituted pentanol derivatives, process for their production and their use as anti-inflammatory agents | IL1B, NFKBIA, BBOX1 | NR3C1 1483/4885PGR 3289/4885NR3C2 872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.